Depression and pegylated interferon-based hepatitis C treatment

Haris Papafragkakis, Murali S. Rao, Martin Moehlen, Sonu Dhillon, Paul Martin

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Interferon remains an essential component of treatment regimens for chronic hepatitis C infection. Mood disturbances, including depression, are relatively common in the hepatitis C virus-infected population and may worsen during hepatitis C treatment. Screening for depression prior to commencement of therapy is crucial and may improve treatment outcomes. Whether prophylactic antidepressant therapy should be initiated prior to therapy of hepatitis C virus infection with an interferon-based regimen remains unclear. We review the epidemiology, diagnosis, and management of depression before and during treatment of hepatitis C virus infection with interferon.

Original languageEnglish (US)
Pages (from-to)25-35
Number of pages11
JournalInternational Journal of Interferon, Cytokine and Mediator Research
Issue number1
StatePublished - Mar 27 2012


  • Cytokines
  • Depression
  • Hepatitis C
  • Pegylated interferon
  • Suicide risk

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'Depression and pegylated interferon-based hepatitis C treatment'. Together they form a unique fingerprint.

Cite this